Ginkgo Bioworks Holdings Inc vs iShares MSCI South Korea ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while iShares MSCI South Korea ETF trades at $175.56. The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | EWY | |
|---|---|---|
Market Cap | $590.53M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $16.14 | $219.20 |
52-Week Low | $5.48 | $70.65 |
Enterprise Value | $627.78M | — |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
EWY, the iShares MSCI South Korea ETF, trades at $168.08, down 8.41% over 24 hours amid a bearish technical signal. The ETF is heavily concentrated in Samsung and SK Hynix, exposing it to volatility in AI-driven semiconductor demand. Recent news highlights South Korean market turbulence, with the Kospi Index experiencing sharp declines and recoveries tied to chip stock performance. Key support lies at $162, with resistance at $171. Financial ratios are unavailable in the provided data, limiting fundamental clarity.
The outlook for EWY hinges on semiconductor cycle dynamics and foreign investor sentiment. Opportunities exist if AI memory demand rebounds, but risks include high concentration in two stocks, global tech volatility, and macroeconomic pressures. The bearish technical trend and neutral oscillators suggest cautious near-term momentum, requiring monitoring of earnings from top holdings for directional cues.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →